A Triple Role for a Bilayer: Using Nanoliposomes to Cross and Protect Cellular Membranes.
Alpha-synuclein
Neurodegenerative diseases
Toxic oligomers
Journal
The Journal of membrane biology
ISSN: 1432-1424
Titre abrégé: J Membr Biol
Pays: United States
ID NLM: 0211301
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
13
10
2020
accepted:
12
11
2020
pubmed:
12
1
2021
medline:
5
3
2022
entrez:
11
1
2021
Statut:
ppublish
Résumé
Thanks in large part to the seminal work of Steve White and his colleagues, we appreciate the "ordered complexity" of the lipid bilayer and how it impacts the incorporation of integral membrane proteins as well as more peripherally associated proteins. Steve's work also provides a vital foundation to tackle another challenge: cytotoxic oligomeric complexes which accumulate in various neurodegenerative diseases. These oligomers have a relatively fluid structure and interact with many different proteins in the cell, but their main target is thought to be the phospholipid membrane, either the plasma membrane or internal organelles such as the mitochondria. This fascinating encounter between two essentially fluid phases generates a more disordered membrane, and presumably promotes uncontrolled transport of small metal ions across the membrane barrier. Happily, this unwanted interaction may be suppressed by mobilizing the phospholipid bilayer into its own defense. Extruded nanolipoparticles (NLPs) consisting of DPPC lipids, cholesterol and PEG2000 are excellent vehicles to take up small "oligomer-bashing" hydrophobic molecules such as baicalein and transport them with increased half-life in the plasma and with markedly more efficient crossing of the blood-brain barrier. Thus the bilayer has a triple role in this account: a safe space for a reactive hydrophobic small molecule, a barrier to cross to deliver a drug payload and a target to protect against oligomer attacks. NLPs containing small hydrophobic molecules show great promise in combating neurodegenerative diseases in animal models and may serve as an example of the White approach: applying robust physical-chemical principles to deal with biological problems involving phospholipid membranes.
Identifiants
pubmed: 33427941
doi: 10.1007/s00232-020-00159-6
pii: 10.1007/s00232-020-00159-6
doi:
Substances chimiques
Lipid Bilayers
0
Phospholipids
0
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
29-39Références
Alam P, Bousset L, Melki R, Otzen DE (2019) alpha-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem 150:522–534
pubmed: 31254394
Aliakbari F, Mohammad-Beigi H, Abbasi S, Rezaei-Ghaleh N, Lermyte F, Parsafar S, Becker S, Tafreshi AP, Farhadpour M, O’Connor PB, Collingwood JF, Christiansen G, Sutherland D, Jensen PH, Morshedi D, Otzen DE (2020) Multiple protective roles of nanoliposome-incorporated baicalein against alpha-synuclein aggregates. Adv Funct Mater 30:2007765
Aliakbari F, Mohammad-Beigi H, Rezaei-Ghaleh N, Becker S, Dehghani Esmatabad F, Eslampanah Seyedi HA, Bardania H, Tayaranian Marvian A, Collingwood JF, Christiansen G, Zweckstetter M, Otzen DE, Morshedi D (2018) The potential of zwitterionic nanoliposomes against neurotoxic alpha-synuclein aggregates in Parkinson’s Disease. Nanoscale 10:9174–9185
pubmed: 29725687
Aliakbari, F, Shabani, AA, Bardania, H, Eslampanah Seyedi, HA, Mohammad-Beigi, H, Tayaranian Marvian, A, Nassoti, M, Vafaei, AA, Shojaosadati, SA, Saboury, AA, Christiansen, G, Morshedi, D (2017). Neurotoxicity of pre-incubated alpha-synuclein with neutral nanoliposomes on PC12 and SHSY5Y cell lines. Scientia Iranica 0:0–0
Aliakbari F, Shabani AA, Bardania H, Mohammad-Beigi H, Tayaranian Marvian A, Dehghani Esmatabad F, Vafaei AA, Shojaosadati SA, Saboury AA, Christiansen G, Otzen DE, Morshedi D (2018) Formulation and anti-neurotoxic activity of baicalein-incorporating neutral nanoliposome. Colloids Surf B Biointerfaces 161:578–587
pubmed: 29149763
Andersen, CB, Yoshimura, Y, Nielsen, J, Otzen, DE, Mulder, FAA (2020). How epigallocatechin gallate binds and assembles oligomeric forms of human alpha-synuclein. Submitted
Angelova PR, Ludtmann MH, Horrocks MH, Negoda A, Cremades N, Klenerman D, Dobson CM, Wood NW, Pavlov EV, Gandhi S, Abramov AY (2016) Ca2+ is a key factor in alpha-synuclein-induced neurotoxicity. J Cell Sci 129:1792–1801
pubmed: 26989132
pmcid: 4893653
Ardah MT, Ghanem SS, Abdulla SA, Lv G, Emara MM, Paleologou KE, Vaikath NN, Lu JH, Li M, Vekrellis K, Eliezer D, El-Agnaf OMA (2020) Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts. BMC Complement Med Ther 20:73
pubmed: 32143619
pmcid: 7076823
Benz RW, Castro-Roman F, Tobias DJ, White SH (2005) Experimental validation of molecular dynamics simulations of lipid bilayers: a new approach. Biophys J 88:805–817
pubmed: 15533925
Benz RW, Nanda H, Castro-Roman F, White SH, Tobias DJ (2006) Diffraction-based density restraints for membrane and membrane-peptide molecular dynamics simulations. Biophys J 91:3617–3629
pubmed: 16950837
pmcid: 1630481
Bolognesi B, Kumita JR, Barros TP, Esbjorner EK, Luheshi LM, Crowther DC, Wilson MR, Dobson CM, Favrin G, Yerbury JJ (2010) ANS binding reveals common features of cytotoxic amyloid species. ACS Chem Biol 5:735–740
pubmed: 20550130
Bozzuto G, Molinari A (2015) Liposomes as nanomedical devices. Int J Nanomedicine 10:975–999
pubmed: 25678787
pmcid: 4324542
Chakraborty S, Doktorova M, Molugu TR, Heberle FA, Scott HL, Dzikovski B, Nagao M, Stingaciu LR, Standaert RF, Barrera FN, Katsaras J, Khelashvili G, Brown MF, Ashkar R (2020) How cholesterol stiffens unsaturated lipid membranes. Proc Natl Acad Sci U S A 117:21896–21905
pubmed: 32843347
pmcid: 7486787
Chen Y, Minh LV, Liu J, Angelov B, Drechsler M, Garamus VM, Willumeit-Romer R, Zou A (2016) Baicalin loaded in folate-PEG modified liposomes for enhanced stability and tumor targeting. Colloids Surf B Biointerfaces 140:74–82
pubmed: 26741267
Davidson WS, Jonas A, Clayton DF, George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273:9443–9449
pubmed: 9545270
Duzgunes N, Nir S (1999) Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev 40:3–18
Fantini J, Barrantes FJ (2009) Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim Biophys Acta 1788:2345–2361
pubmed: 19733149
Fantini J, Carlus D, Yahi N (2011) The fusogenic tilted peptide (67–78) of alpha-synuclein is a cholesterol binding domain. Biochim Biophys Acta 1808:2343–2351
pubmed: 21756873
Fusco G, Chen SW, Williamson PTF, Cascella R, Perni M, Jarvis JA, Cecchi C, Vendruscolo M, Chiti F, Cremades N, Ying L, Dobson CM, De Simone A (2017) Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers. Science 358:1440–1443
pubmed: 29242346
Galvagnion C, Buell AK, Meisl G, Michaels TCT, Vendruscolo M, Knowles TJ, Dobson CM (2015) Lipid vesicles trigger a-synuclein aggregation by stimulating primary nucleation. Nature Struct. Mol, Biol (In press)
Gao Z, Huang K, Yang X, Xu H (1999) Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta 1472:643–650
pubmed: 10564778
Gong WY, Zhao ZX, Liu BJ, Lu LW, Dong JC (2017) Exploring the chemopreventive properties and perspectives of baicalin and its aglycone baicalein in solid tumors. Eur J Med Chem 126:844–852
pubmed: 27960146
Hong D-P, Fink AL, Uversky VN (2008) Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J Mol Biol 383:214–223
pubmed: 18775438
pmcid: 2573395
Hu Q, Uversky VN, Huang M, Kang H, Xu F, Liu X, Lian L, Liang Q, Jiang H, Liu A, Zhang C, Pan-Montojo F, Zhu S (2016) Baicalein inhibits alpha-synuclein oligomer formation and prevents progression of alpha-synuclein accumulation in a rotenone mouse model of Parkinson’s disease. Biochim Biophys Acta 1862:1883–1890
pubmed: 27425033
Ishii T, Mori T, Tanaka T, Mizuno D, Yamaji R, Kumazawa S, Nakayama T, Akagawa M (2008) Covalent modification of proteins by green tea polyphenol (-)-epigallocatechin-3-gallate through autoxidation. Free Radic Biol Med 45:1384–1394
pubmed: 18771724
Jacobs RE, White SH (1989) The nature of the hydrophobic binding of small peptides at the bilayer interface: implications for the insertion of transbilayer helices. Biochemistry 28:3421–3437
pubmed: 2742845
Jia X, Jia M, Yang Y, Wang D, Zhou F, Zhang W, Huang X, Guo W, Cai D, Chen H, Qi J, Zhou S, Ren H, Xu B, Ma T, Wang P, Lei H (2019) Synthesis of Novel Baicalein Amino Acid Derivatives and Biological Evaluation as Neuroprotective Agents. Molecules 24(20):3647
pmcid: 6832219
Jiang M, Porat-Shliom Y, Pei Z, Cheng Y, Xiang L, Sommers K, Li Q, Gillardon F, Hengerer B, Berlinicke C, Smith WW, Zack DJ, Poirier MA, Ross CA, Duan W (2010) Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. J Neurochem 114:419–429
pubmed: 20412383
pmcid: 2910156
Kamps JA (2010) Assessment of liposome-cell interactions. Methods Mol Biol 606:199–207
pubmed: 20013399
Ke PC, Zhou R, Serpell LC, Riek R, Knowles TPJ, Lashuel HA, Gazit E, Hamley IW, Davis TP, Fandrich M, Otzen DE, Chapman MR, Dobson CM, Eisenberg DS, Mezzenga R (2020) Half a century of amyloids: past, present and future. Chem Soc Rev 49:5473–5509
pubmed: 32632432
Kim, TY, Leem, E, Lee, JM, Kim, SR (2020). Control of Reactive Oxygen Species for the Prevention of Parkinson's Disease: The Possible Application of Flavonoids. Antioxidants (Basel) 9
Kjær L, Giehm L, Heimburg T, Otzen DE (2009) The influence of vesicle composition and size on a-synuclein structure and stability. Biophys J 96:2857–2870
pubmed: 19348768
pmcid: 2711279
Knudsen KB, Northeved H, Kumar PE, Permin A, Gjetting T, Andresen TL, Larsen S, Wegener KM, Lykkesfeldt J, Jantzen K, Loft S, Moller P, Roursgaard M (2015) In vivo toxicity of cationic micelles and liposomes. Nanomedicine 11:467–477
pubmed: 25168934
Lashuel HA, Hartley D, Petre BM, Weals T, Lansbury PT (2002) Amyloid pores from pathogenic mutations. Nature 418:291
pubmed: 12124613
Lashuel, HA, Lansbury, PT (2006). Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Quart. Rev. Biophys.:1–35
Lasic DD, Vallner JJ, Working PK (1999) Sterically stabilized liposomes in cancer therapy and gene delivery. Curr Opin Mol Ther 1:177–185
pubmed: 11715941
Lautenschlager J, Stephens AD, Fusco G, Strohl F, Curry N, Zacharopoulou M, Michel CH, Laine R, Nespovitaya N, Fantham M, Pinotsi D, Zago W, Fraser P, Tandon A, St George-Hyslop P, Rees E, Phillips JJ, De Simone A, Kaminski CF, Schierle GSK (2018) C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction. Nat Commun 9:712
pubmed: 29459792
pmcid: 5818535
Levin, J, Maass, S, Schuberth, M, Giese, A, Oertel, WH, Poewe, W, Trenkwalder, C, Wenning, GK, Mansmann, U, Sudmeyer, M, Eggert, K, Mollenhauer, B, Lipp, A, Lohle, M, Classen, J, Munchau, A, Kassubek, J, Gandor, F, Berg, D, Egert-Schwender, S, Eberhardt, C, Paul, F, Botzel, K, Ertl-Wagner, B, Huppertz, HJ, Ricard, I, Hoglinger, GU, Group, PS (2019) Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 18:724–735
Levitan K, Chereau D, Cohen SI, Knowles TP, Dobson CM, Fink AL, Anderson JP, Goldstein JM, Millhauser GL (2011) Conserved C-terminal charge exerts a profound influence on the aggregation rate of alpha-synuclein. J Mol Biol 411:329–333
pubmed: 21689664
pmcid: 3143250
Li W, Pi J, Zhang Y, Ma X, Zhang B, Wang S, Qi D, Li N, Guo P, Liu Z (2018) A strategy to improve the oral availability of baicalein: The baicalein-theophylline cocrystal. Fitoterapia 129:85–93
pubmed: 29936192
Liang J, Wu W, Liu Q, Chen S (2013) Long-circulating nanoliposomes (LCNs) sustained delivery of baicalein (BAI) with desired oral bioavailability in vivo. Drug Deliv 20:319–323
pubmed: 24028326
Lim, L, Wenk, MR (2009). Handbook of Neurochemistry and Molecular Neurobiology Springer, Boston.
Liu JP, Tang Y, Zhou S, Toh BH, McLean C, Li H (2010) Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Mol Cell Neurosci 43:33–42
pubmed: 19660552
Liu Q, Li J, Pu G, Zhang F, Liu H, Zhang Y (2016) Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy. Drug Deliv 23:1364–1368
pubmed: 25874959
Lorenzen N, Nielsen SB, Yoshimura Y, Andersen CB, Betzer C, Vad BS, Kaspersen JD, Christiansen G, Pedersen JS, Jensen PH, Mulder FA, Otzen DE (2014) How epigallogatechin gallate can inhibit α-synuclein oligomer toxicity in vitro. J Biol Chem 289:21299–21310
pubmed: 24907278
pmcid: 4118093
Mannini B, Mulvihill E, Sgromo C, Cascella R, Khodarahmi R, Ramazzotti M, Dobson CM, Cecchi C, Chiti F (2014) Toxicity of protein oligomers is rationalized by a function combining size and surface hydrophobicity. ACS Chem Biol 9:2309–2317
pubmed: 25079908
Matsuzaki K (2019) Membrane Permeabilization Mechanisms. Adv Exp Med Biol 1117:9–16
pubmed: 30980350
Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer-Hartl M, Hartl FU, Vabulas RM (2011) Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144:67–78
pubmed: 21215370
Otzen DE (2015) Protein aggregation: Close encounters of the greasy kind. Nature Chem Biol 11:176–177
Palhano FL, Lee J, Grimster NP, Kelly JW (2013) Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J Am Chem Soc 135:7503–7510
pubmed: 23611538
pmcid: 3674815
Pardridge WM (2017) Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology. BioDrugs 31:503–519
pubmed: 29067674
Paslawski W, Lorenzen N, Otzen DE (2016) Formation and characterization of α-synuclein oligomers. Methods Mol Biol 1345:133–150
pubmed: 26453210
Paslawski W, Mysling S, Thomsen K, Jørgensen TJD, Otzen DE (2014) Co-existence of two different α-synuclein oligomers with different core structures determined by Hydrogen/Deuterium Exchange Mass Spectrometry. Angew Chem Int Ed Engl 53:7560–7563
pubmed: 24740651
Ross C, Taylor M, Fullwood N, Allsop D (2018) Liposome delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine 13:8507–8522
pubmed: 30587974
pmcid: 6296687
Sang S, Lee MJ, Hou Z, Ho CT, Yang CS (2005) Stability of tea polyphenol (-)-epigallocatechin-3-gallate and formation of dimers and epimers under common experimental conditions. J Agric Food Chem 53:9478–9484
pubmed: 16302765
Shah V, Taratula O, Garbuzenko OB, Patil ML, Savla R, Zhang M, Minko T (2013) Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids. Curr Drug Discov Technol 10:8–15
pubmed: 22564170
pmcid: 3899095
Srinivas NR (2010) Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica 40:357–367
pubmed: 20230189
Sternke-Hoffmann R, Peduzzo A, Bolakhrif N, Haas R, Buell AK (2020) The Aggregation Conditions Define Whether EGCG is an Inhibitor or Enhancer of alpha-Synuclein Amyloid Fibril Formation. Int J Mol Sci 21:1995
pmcid: 7139648
Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW (2011) Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect 119:866–872
pubmed: 21269927
pmcid: 3114824
Tu B, Li RR, Liu ZJ, Chen ZF, Ouyang Y, Hu YJ (2016) Structure-activity relationship study between baicalein and wogonin by spectrometry, molecular docking and microcalorimetry. Food Chem 208:192–198
pubmed: 27132840
van Diggelen F, Frank SA, Somavarapu AK, Scavenius C, Apetri MM, Nielsen J, Tepper A, Enghild JJ, Otzen DE (2020) The interactome of stabilized alpha-synuclein oligomers and neuronal proteins. FEBS J 287:2037–2054
pubmed: 31686426
van Diggelen F, Tepper AWJW, Apetri MM, Otzen DE (2017) a-synuclein oligomers: a study in diversity. Israel J Chem 57:699–723
van Maarschalkerweerd A, Vetri V, Vestergaard B (2015) Cholesterol facilitates interactions between alpha-synuclein oligomers and charge-neutral membranes. FEBS Lett 589:2661–2667
pubmed: 26297828
Varypataki EM, Silva AL, Barnier-Quer C, Collin N, Ossendorp F, Jiskoot W (2016) Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles. J Control Release 226:98–106
pubmed: 26876760
White SH, Jacobs RE (1990) Statistical distribution of hydrophobic residues along the length of protein chans. Implications for protein folding and evolution. Biophys J 57:911–921
pubmed: 2188687
pmcid: 1280792
Wimley WC, Hristova K, Ladokhin AS, Silvestro L, Axelsen PH, White SH (1998) Folding of b-sheet membrane proteins: a hydrophobic hexapeptide model. J Mol Biol 277:1091–1110
pubmed: 9571025
Wimley WC, White SH (1996) Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nature Struct Biol 3:842–848
pubmed: 8836100
Woo AY, Cheng CH, Waye MM (2005) Baicalein protects rat cardiomyocytes from hypoxia/reoxygenation damage via a prooxidant mechanism. Cardiovasc Res 65:244–253
pubmed: 15621053
Xing J, Chen X, Zhong D (2005) Absorption and enterohepatic circulation of baicalin in rats. Life Sci 78:140–146
pubmed: 16107266
Zhang H, Zhao L, Chu L, Han X, Zhai G (2014) Preparation, optimization, characterization and cytotoxicity in vitro of Baicalin-loaded mixed micelles. J Colloid Interface Sci 434:40–47
pubmed: 25168581
Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL (2004) The flavonoid baicalein inhibits fibrillation of a-synuclein and disaggregates existing fibrils. J Biol Chem 279:26846–26857
pubmed: 15096521